<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6680</article-id>
      <article-id pub-id-type="doi">10.51847/l21Qr0rK1S</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Analysis of the Antimicrobial Drugs Market in Russia</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>17</day>
        <month>04</month>
        <year>2023</year>
      </pub-date>
      <volume>14</volume>
      <issue>2</issue>
      <fpage>30</fpage>
      <lpage>36</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Most inflammatory diseases in the human body are provoked by microorganisms. Bronchitis, pneumonia, otitis media, conjunctivitis, cystitis, endometritis, inflammation of the fallopian tubes and ovaries, and many other diseases in modern treatment protocols of all countries contain antimicrobial substances. Treatment of various bacterial infections (for example, chlamydia, scarlet fever, streptodermia, meningitis, and tuberculosis) is impossible without antimicrobial therapy. Viral diseases (herpes infections, chickenpox, hepatitis B and C, HIV) at the present stage are susceptible to the effects of antiviral drugs. Fungal diseases of the skin, nails, mucous membranes, and systemic mycoses are treated with antibiotics. Protozoa cause such protozoal infections as giardiasis, amoebic dysentery, trichomoniasis, malaria, and toxoplasmosis. In such infections, antiprotozoal antimicrobial medications are prescribed. Thus, the spectrum of effects of these agents is directed at bacteria, fungi, viruses, and protozoa. This article provides a brief description of the types of antimicrobials, as well as an analysis of the antimicrobial drugs market in Russia.</p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>